Polomar Health names Douglas Beck chief financial officer
Tickers PMHS
Douglas Beck became chief financial officer and treasurer effective July 15, 2026, and serves as principal financial and accounting officer. He is a licensed certified public accountant.
Key facts
- Company
- Polomar Health Services, Inc. (OTC: PMHS)
- News type
- Company Updates
- Primary source
- Polomar Health Services, Inc. 8-K (2026-07-20)

Polomar Health Services, Inc. reported in a Form 8-K filed July 20, 2026 that its board appointed Douglas Beck as chief financial officer and treasurer on July 15, 2026, effective that day. Mr. Beck serves as the company's principal financial officer and principal accounting officer. The filing says there are no arrangements or understandings between Mr. Beck and any other person under which he was appointed. It also says there are no family relationships between him and any director or executive officer of the company, and no transactions in which he has a material interest that would require disclosure.
The report was signed by Terrence M. Tierney, the company's president and interim chief executive officer.
His background
The filing says Mr. Beck, age 65, served as chief financial officer of AiAdvertising, Inc. from November 2024 to April 2025 and as chief financial officer of ShiftPixy, Inc. from January 2023 to March 2024. He was a consultant to Beyond Air Inc. from September 2021 to December 2022, and earlier served as its chief financial officer from November 2018 to August 2021. He received a Bachelor of Science in Accounting from Fairleigh Dickinson University and is also a licensed Certified Public Accountant.
The company
The annual report filed May 6, 2026 describes Polomar as a development stage company with a limited operating history. The company says it is at an early stage of marketing and sales, has limited sales history and has a history of net losses. It expects to keep incurring net losses for the foreseeable future and says it may never become profitable.
The risk factors also say the company is subject to significant related party short term debt and other current liabilities, which it may be unable to repay. Its management and independent auditors have identified internal control deficiencies that they believe constitute material weaknesses.
The same risk summary describes a limited trading market for the common stock, and says the company cannot assure holders that the stock will ever be listed on a securities exchange. It notes that the common stock is subject to the penny stock rules of the SEC, which make transactions cumbersome and may reduce the value of an investment. The company also says its largest shareholder and its affiliates have substantial control over the company and its policies.
The company also describes its business plan as unproven, and says it may be unable to complete the roll-out of its business and services without additional financing. Net loss for 2025 was larger than revenue for the same year, as the figures below show.
Financial figures
SEC XBRL data reports revenue of $648,231 for the fiscal year ended December 31, 2025, compared with $58,824 for 2024. Net loss was $10.7 million for 2025 and $1.3 million for 2024. Cash from operations was negative $395,995 in 2025 and negative $1.0 million in 2024. Year-end cash and cash equivalents were $132,150 at the end of 2025. The data also shows cash and cash equivalents of $87,818 at March 31, 2026.
What comes next
The filing does not describe any further finance or accounting plans. The annual report says that if the company fails to obtain additional financing, it may be unable to complete the roll-out of its business and services. A new chief financial officer will take over the reporting duties that the principal financial and accounting officer role carries.
aibio